Anzeige
Mehr »
Freitag, 16.05.2025 - Börsentäglich über 12.000 News
Verpasst du gerade die Buffett-Aktie der neuen Generation?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0DLB7 | ISIN: CA88337V1004 | Ticker-Symbol: TTX
Frankfurt
15.05.25 | 08:01
0,108 Euro
-1,82 % -0,002
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
THERALASE TECHNOLOGIES INC Chart 1 Jahr
5-Tage-Chart
THERALASE TECHNOLOGIES INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,1020,12515.05.

Aktuelle News zur THERALASE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
05.05.Theralase Technologies Inc.: Theralase Clinical Data Presented at Canadian Bladder Cancer Forum and American Urological Association190Toronto, Ontario--(Newsfile Corp. - May 5, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the...
► Artikel lesen
28.04.Theralase Technologies Inc: Theralase finds drug inhibits deubiquitinating enzymes2
28.04.Theralase uncovers new use-case for flagship drug3
THERALASE Aktie jetzt für 0€ handeln
28.04.Theralase Technologies Inc.: Theralase Discovers New Mechanism of Action of Lead Drug247Toronto, Ontario--(Newsfile Corp. - April 28, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the...
► Artikel lesen
23.04.Theralase Technologies Inc: Theralase 1,995,829-share private placement2
15.04.Theralase Technologies Inc: Theralase closes $419,124 private placement2
14.04.Theralase Technologies Inc.: Theralase(R) Closes Non-Brokered Private Placement299Toronto, Ontario--(Newsfile Corp. - April 14, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the...
► Artikel lesen
10.04.Theralase Technologies Inc: Theralase treats herpes-infected mice with ruvidar1
10.04.Theralase Technologies Inc.: Ruvidar More Effective in the Treatment of Herpes than FDA-Approved Treatments195Toronto, Ontario--(Newsfile Corp. - April 10, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the...
► Artikel lesen
07.04.Theralase Technologies Inc: Theralase sees patient complete response in NMIBC study1
07.04.Theralase Technologies Inc.: Ruvidar Demonstrates 7 Year Complete Response263Toronto, Ontario--(Newsfile Corp. - April 7, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the...
► Artikel lesen
24.03.Theralase Technologies Inc: Theralase talks efficacy of Ruvidar in HSV-1 treatment2
24.03.Theralase's Ruvidar excels in preclinical herpes treatment1
24.03.Theralase Technologies Inc.: Ruvidar Effective in the Treatment of Herpes309Toronto, Ontario--(Newsfile Corp. - March 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the...
► Artikel lesen
20.03.Theralase Technologies Inc: Theralase 1,034,002-share private placement8
12.03.Theralase Technologies Inc.: Theralase(R) Releases 2024 Annual Financial Statements229Toronto, Ontario--(Newsfile Corp. - March 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the...
► Artikel lesen
11.03.Theralase Technologies Inc: Theralase closes $310,200 private placement7
11.03.Theralase Technologies Inc.: Theralase(R) Closes Non-Brokered Private Placement328Toronto, Ontario--(Newsfile Corp. - March 11, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the...
► Artikel lesen
10.03.Theralase Technologies Inc: Theralase data show functions improve with TLC-24001
10.03.Theralase Technologies Inc.: Theralase(R) Therapy Improves Motor and Non-Motor Function in Parkinson's Patients253Toronto, Ontario--(Newsfile Corp. - March 10, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the...
► Artikel lesen
Seite:  Weiter >>
51 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1